Entry Point Capital, LLC Summit Therapeutics Inc. Call Options Transaction History
Entry Point Capital, LLC
- $112 Billion
- Q1 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding SMMT
# of Institutions
107Shares Held
41.3MCall Options Held
103KPut Options Held
29.9K-
Black Rock Inc. New York, NY9.82MShares$74.2 Million0.0% of portfolio
-
State Street Corp Boston, MA8.11MShares$61.3 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA7.27MShares$54.9 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA3.15MShares$23.8 Million0.0% of portfolio
-
Northern Trust Corp Chicago, IL1.07MShares$8.1 Million0.0% of portfolio
About Summit Therapeutics Inc.
- Ticker SMMT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 201,215,008
- Market Cap $1.52B
- Description
- Summit Therapeutics Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat infectious diseases in the United States and Latin America. It conducts clinical programs focusing on Clostridioides difficile infection (CDI). The company's lead product candidate is ridinilazole, an orally administered small molecu...